Edward M Vital

11.3k total citations · 2 hit papers
147 papers, 3.9k citations indexed

About

Edward M Vital is a scholar working on Rheumatology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Edward M Vital has authored 147 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Rheumatology, 64 papers in Immunology and 47 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Edward M Vital's work include Systemic Lupus Erythematosus Research (91 papers), Monoclonal and Polyclonal Antibodies Research (47 papers) and Rheumatoid Arthritis Research and Therapies (38 papers). Edward M Vital is often cited by papers focused on Systemic Lupus Erythematosus Research (91 papers), Monoclonal and Polyclonal Antibodies Research (47 papers) and Rheumatoid Arthritis Research and Therapies (38 papers). Edward M Vital collaborates with scholars based in United Kingdom, United States and Sweden. Edward M Vital's co-authors include Paul Emery, Shouvik Dass, Md Yuzaiful Md Yusof, Andy C. Rawstron, Antonios Psarras, Miriam Wittmann, Maya H Buch, Colin Pease, Karen Henshaw and Frédérique Ponchel and has published in prestigious journals such as The Lancet, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Edward M Vital

132 papers receiving 3.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

2019 289 citations Ian N Bruce, Edward M Vital et al. profile →
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)

2023 79 citations Edward M Vital et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edward M Vital United Kingdom	34	2.6k	2.0k	995	567	509	147	3.9k
Paul Brunetta United States	18	2.6k 1.0×	1.7k 0.9×	1.2k 1.2×	446 0.8×	343 0.7×	30	3.7k
D. Close United States	15	1.5k 0.6×	1.2k 0.6×	807 0.8×	382 0.7×	362 0.7×	26	3.0k
Andreas Jönsen Sweden	37	2.6k 1.0×	2.5k 1.3×	638 0.6×	417 0.7×	555 1.1×	105	3.9k
Rogier M. Thurlings Netherlands	29	1.4k 0.6×	997 0.5×	578 0.6×	388 0.7×	343 0.7×	72	2.8k
Kyriakos A. Kirou United States	34	2.6k 1.0×	2.9k 1.5×	640 0.6×	526 0.9×	766 1.5×	73	4.3k
Anna Filipowicz‐Sosnowska Poland	8	1.8k 0.7×	1.1k 0.6×	798 0.8×	509 0.9×	345 0.7×	36	3.4k
Satoshi Kubo Japan	32	1.6k 0.6×	1.2k 0.6×	252 0.3×	415 0.7×	491 1.0×	157	3.0k
Gurtej S. Cheema United States	24	1.3k 0.5×	1.2k 0.6×	411 0.4×	489 0.9×	266 0.5×	26	2.9k
Tim Shaw United States	9	1.3k 0.5×	902 0.5×	640 0.6×	429 0.8×	272 0.5×	16	2.5k
Gian Domenico Sebastiani Italy	30	3.1k 1.2×	1.9k 1.0×	760 0.8×	590 1.0×	268 0.5×	109	4.3k

Countries citing papers authored by Edward M Vital

Since Specialization

Citations

This map shows the geographic impact of Edward M Vital's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward M Vital with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward M Vital more than expected).

Fields of papers citing papers by Edward M Vital

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward M Vital. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward M Vital. The network helps show where Edward M Vital may publish in the future.

Co-authorship network of co-authors of Edward M Vital

This figure shows the co-authorship network connecting the top 25 collaborators of Edward M Vital. A scholar is included among the top collaborators of Edward M Vital based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward M Vital. Edward M Vital is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Teng, Y K Onno, et al.. (2025). Opportunities and limitations of B cell depletion approaches in SLE. Nature Reviews Rheumatology. 21(2). 111–126. 15 indexed citations

Marco, Gabriele De, Katya Meridor, Tom Macleod, et al.. (2025). Late‐Onset Spondyloarthritis Presenting as Glucocorticoid‐Resistant Polymyalgia Rheumatica: A Hitherto Underappreciated Entity in Which Tumor Necrosis Factor or Interleukin ‐17 Blockade May Have a Therapeutic Role. Arthritis & Rheumatology. 78(1). 131–140.

Carter, L. M., Md Yuzaiful Md Yusof, Darren Plant, et al.. (2024). Blood RNA-sequencing across the continuum of ANA-positive autoimmunity reveals insights into initiating immunopathology. Annals of the Rheumatic Diseases. 83(10). 1322–1334. 3 indexed citations

Carter, L. M., et al.. (2024). ANA-associated arthritis: clinical and biomarker characterization of a population for basket trials. Lara D. Veeken. 63(11). 3135–3145.

Mahmoud, Khaled, Michelle Wilson, Md Yuzaiful Md Yusof, et al.. (2024). O14 Rituximab objective outcome measures trial in SLE (ROOTS): outcomes of randomised and rescue rituximab therapy in a double-blind randomised placebo-controlled trial. SHILAP Revista de lepidopterología. A16.2–A17.

Psarras, Antonios, et al.. (2024). P24 Differentiated monocytes express the pDC markers BDCA-2 and CD123. SHILAP Revista de lepidopterología. A59.2–A59. 1 indexed citations

Mahmoud, Khaled, Md Yuzaiful Md Yusof, Lee Suan Teh, et al.. (2024). Improving the arthritis component of the SLEDAI-2K. Lara D. Veeken. 64(6). 3556–3562. 1 indexed citations

Burska, Agata, Javier Rodríguez‐Carrio, Robert Biesen, et al.. (2023). Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. RMD Open. 9(1). e002876–e002876. 12 indexed citations

Psarras, Antonios, et al.. (2023). AB0115 CD14+ MYELOID CELLS EXPRESS THE PDC MARKERS BDCA-2, BDCA-4, CD123 UPON DIFFERENTIATION IN BOTH HEALTHY INDIVIDUALS AND SLE PATIENTS. Annals of the Rheumatic Diseases. 82. 1236–1236. 2 indexed citations

10.

Edwards, Christopher J, Michael R. Ehrenstein, Bridget Griffiths, et al.. (2023). Differences in management approaches for lupus nephritis within the UK. Rheumatology Advances in Practice. 8(1). rkae017–rkae017. 3 indexed citations

11.

Sandler, Robert D, Edward M Vital, Khaled Mahmoud, et al.. (2023). Revision to the musculoskeletal domain of the BILAG-2004 index to incorporate ultrasound findings. Lara D. Veeken. 63(2). 498–505. 5 indexed citations

12.

Carter, L. M., et al.. (2023). Adaptation of the Russian version of the activity index of systemic lupus erythematosus EASY-BILAG. SHILAP Revista de lepidopterología. 17(5). 107–111.

13.

Carter, L. M., Caroline Gordon, Chee‐Seng Yee, et al.. (2021). Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. Lara D. Veeken. 61(10). 4006–4015. 20 indexed citations

14.

Yusof, Md Yuzaiful Md, M. I. Darby, Edward M Vital, et al.. (2020). THU0143 EFFECT OF RITUXIMAB OR TUMOUR NECROSIS FACTOR INHIBITORS ON LUNG INFECTION AND 5-YEAR SURVIVAL IN RHEUMATOID ARTHRITIS-ASSOCIATED BRONCHIECTASIS. Annals of the Rheumatic Diseases. 79. 286–287. 1 indexed citations

15.

El‐Sherbiny, Yasser M., Md Yuzaiful Md Yusof, Antonios Psarras, et al.. (2019). B Cell Tetherin: A Flow Cytometric Cell‐Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus. Arthritis & Rheumatology. 72(5). 769–779. 16 indexed citations

16.

Sellam, Jérémie, Élodie Rivière, Alice Courties, et al.. (2016). Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Research & Therapy. 18(1). 294–294. 26 indexed citations

17.

Alase, Adewonuola, Yasser M. El‐Sherbiny, Edward M Vital, et al.. (2015). IFNλ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism. Journal of Investigative Dermatology. 135(12). 2935–2943. 21 indexed citations

18.

Isenberg, David, Anisur Rahman, David Jayne, et al.. (2014). Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register. UCL Discovery (University College London). 1 indexed citations

19.

Yusof, Md Yuzaiful Md, Edward M Vital, & Paul Emery. (2014). Biologics in systemic lupus erythematosus: current options and future perspectives. British Journal of Hospital Medicine. 75(8). 440–447. 8 indexed citations

20.

Dass, S., Simon Bowman, Edward M Vital, et al.. (2008). Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Annals of the Rheumatic Diseases. 67(11). 1541–1544. 262 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact